Trius Therapeutics, Inc. (TSRX)

[surf1944]

8:03AM Trius Therapeutics receives QIDP designation from FDA (TSRX) 5.21 : Co announces the FDA has designated the company's Phase 3 antibiotic candidate, tedizolid phosphate, as a Qualified Infectious Disease Product (QIDP). Co received the designation for its current Phase 3 program of tedizolid for acute bacterial skin and skin structure infections as well as the planned Phase 3 program for hospital-acquired/ventilator-associated bacterial pneumonia. In addition, the designations were granted for both the intravenous and oral dosage forms of tedizolid. The QIDP designation will enable co to benefit from certain incentives for the development of new antibiotics, including priority review and eligibility for fast-track status.